LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)...
Hence then, the article about hansa biopharma data at the 2025 pns annual meeting demonstrates potential of imlifidase in the treatment of gbs was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS )
Also on site :
- Iran war live: Trump claims US Navy blockade stops Iranian ships in Hormuz
- ServiceNow CFO says leaders working 14 hours and getting 4 hours of sleep set a ‘terrible example’ for their employees
- Brad Caleb Kane Teases ‘It: Welcome to Derry’ Is “Bigger” In Season 2 With “A Different Kind Of Pennywise”